NOV 17, 202662 MINS READ
Croscarmellose Sodium (also known as Ac-Di-Sol®) is an internally cross-linked sodium carboxymethylcellulose characterized by its rapid swelling capacity and water-wicking properties 3. Unlike linear cellulose derivatives, the cross-linked three-dimensional network structure allows the polymer chains to absorb water rapidly (up to 8–10 times its own weight within seconds) without dissolving, thereby generating substantial localized swelling pressure that disrupts tablet matrix integrity 7. This mechanism is fundamentally different from crospovidone, which relies primarily on capillary action, and sodium starch glycolate, which exhibits slower hydration kinetics 15.
The superdisintegrant classification of Croscarmellose Sodium stems from its ability to achieve effective disintegration at significantly lower concentrations (2–4% w/w) compared to conventional disintegrants like corn starch (10–15% w/w) 6. Comparative studies demonstrate that at 2% concentration, Croscarmellose Sodium achieves disintegration times of approximately 18–22 seconds in ODTs compressed at 6–8 kN, whereas crospovidone (PVP XL-10) at 5% concentration requires 30–40 seconds under identical conditions 7. The molecular-level explanation involves the ionization of carboxymethyl groups (–CH₂COO⁻Na⁺) in aqueous media, creating electrostatic repulsion between polymer chains that amplifies the swelling force and accelerates matrix breakdown 37.
Key structural parameters influencing disintegration performance include:
The disintegration kinetics follow a two-stage process: initial rapid water penetration (0–5 seconds) driven by capillary forces through inter-particulate voids, followed by explosive swelling (5–20 seconds) as Croscarmellose Sodium particles expand and generate disruptive forces exceeding the tablet's tensile strength (typically 0.5–2.0 MPa for ODTs) 7. Texture analyzer studies reveal that Croscarmellose Sodium-containing ODTs exhibit a gradual softening pattern with earlier initiation of disintegration compared to the delayed-then-sudden pattern observed with crospovidone, resulting in superior mouthfeel perception by 80% of trained panelists 7.
Extensive formulation development studies establish that Croscarmellose Sodium functions optimally in Orally Disintegrating Tablets at concentrations between 3.5% and 8.0% w/w of total tablet weight 126. This range represents a critical balance between achieving rapid disintegration (target: <30 seconds) and maintaining sufficient mechanical strength (hardness: 40–70 N; tensile strength: >0.5 MPa) to withstand manufacturing, packaging, and handling stresses 7.
Concentration-Performance Relationships:
Comparative analysis against alternative superdisintegrants demonstrates Croscarmellose Sodium's efficiency advantage: achieving equivalent disintegration performance at 2% versus 5% for crospovidone (PVP XL-10) or sodium starch glycolate 7. Corn starch, crospovidone, and croscarmellose calcium were systematically evaluated and rejected due to inadequate disintegration times and/or mechanical defects (cleavage, high friability) 126.
Phase Distribution Strategy:
A critical formulation parameter unique to Croscarmellose Sodium in ODTs involves its distribution between the intra-granular (internal) and extra-granular (external) phases during tablet manufacturing 126. Optimal disintegration kinetics are achieved by allocating approximately 50% of total Croscarmellose Sodium to each phase—a 50:50 distribution yields 20-second disintegration, whereas 25:75 or 75:25 distributions result in disintegration times exceeding 40 seconds (more than double) 16. This phenomenon is attributed to the dual-action mechanism: intra-granular Croscarmellose Sodium disrupts granule integrity from within, while extra-granular material facilitates inter-granular separation and water penetration pathways 2.
Granulation Process Considerations:
When incorporating Croscarmellose Sodium via wet granulation, the material should be prepared as an aqueous slurry at 2–15% concentration relative to the active pharmaceutical ingredient (API) weight, preferably 5–12% 5. Critical process controls include:
The slurry-based incorporation method enhances API particle coating, which is particularly beneficial for water-soluble actives that might otherwise exhibit delayed release 5. Notably, sodium starch glycolate develops undesirable ropy consistency in slurry form, while crospovidone fails to provide adequate particle coverage—both factors contributing to Croscarmellose Sodium's preferential selection 5.
The performance of Croscarmellose Sodium in Orally Disintegrating Tablets is profoundly influenced by co-formulated excipients, particularly fillers/diluents, binders, and lubricants. Rational excipient selection based on physicochemical compatibility and functional synergy is essential for achieving target product profiles.
Mannitol emerges as the preferred diluent for Croscarmellose Sodium-based ODTs, typically incorporated at 55–70% w/w with particle size range of 30–300 μm (mean diameter ~160 μm) 126. Comparative evaluations demonstrate that lactose, sorbitol, and excessive microcrystalline cellulose (MCC) all produce unacceptably long disintegration times or undesirable organoleptic properties 126. Mannitol's advantages include:
Spray-dried mannitol specifically demonstrates superior performance in low-superdisintegrant ODT formulations (0.5–2.0% Croscarmellose Sodium), achieving <30-second disintegration after four months of accelerated stability testing (40°C/75% RH) 7.
Microcrystalline Cellulose (MCC) serves dual functions as binder and secondary filler at 10–20% w/w concentration 126. Particle size significantly impacts ODT performance:
Excessive MCC content (>25% w/w) creates production challenges with conventional tablet presses due to increased ejection forces and causes undesirable gustatory perception (cellulose mouthfeel) 26. The recommended MCC range of 10–20% provides sufficient binding without interfering with Croscarmellose Sodium's disintegration mechanism 36.
Advanced ODT formulations employ co-processed excipients combining MCC with other functional components. A particularly effective system comprises 75–95% MCC with 5–25% calcium-sodium alginate complex at 10–50% total tablet weight, used alongside 1–6% Croscarmellose Sodium and 10–50% additional MCC 3. This co-processed additive enhances:
Recent innovations include self-disintegrating co-processed excipients manufactured by spray-drying or flash-drying homogeneous slurries of cellulose binder, MCC, and 0.5–15% Croscarmellose Sodium at 30–100°C 8. These systems exhibit mean particle size of 90–150 μm and bulk density of 0.25–0.50 g/mL, optimized for direct compression ODT manufacturing 8.
Magnesium stearate at 0.5–1.5% w/w represents the standard lubricant choice for Croscarmellose Sodium ODT formulations 126. Critical considerations include:
Alternative lubricants such as sodium stearyl fumarate, stearic acid, and talc may be employed at 0.2–1.0% w/w, with sodium stearyl fumarate offering reduced hydrophobicity compared to magnesium stearate 8.
While Croscarmellose Sodium itself provides some binding capacity through its fibrous structure, additional binders may be incorporated for specific applications. Maltodextrin at ≥2% w/w serves as a water-soluble binder in orodispersible domperidone formulations, contributing to granule integrity without compromising disintegration 126.
Emerging formulations incorporate 0.5–5% w/w of hydrophobic polymers—including (meth)acrylic polymers, ethyl cellulose, cellulose acetate, hydroxypropylmethylcellulose acetate succinate (HPMCAS), or hydroxypropylmethylcellulose phthalate (HPMCP)—to enhance tablet moldability and moisture resistance while maintaining disintegration performance when combined with 3–8% Croscarmellose Sodium 4. These polymers create a controlled-release microenvironment that modulates water ingress without preventing Croscarmellose Sodium activation.
The translation of Croscarmellose Sodium formulations from laboratory-scale development to commercial manufacturing requires precise control of multiple process parameters to ensure consistent disintegration performance, mechanical strength, and stability.
Compression force directly influences the balance between tablet hardness and disintegration time. Systematic studies demonstrate:
The optimal compression force window for Croscarmellose Sodium ODTs typically ranges from 7–9 kN, producing tablets with tensile strength of 0.5–1.5 MPa—sufficient to withstand a 1-meter drop test while maintaining <25-second disintegration 7. Excessive compression (>12 kN) causes plastic deformation of Croscarmellose Sodium particles, reducing their swelling capacity and significantly impairing disintegration kinetics 7.
Wet Granulation Approach:
When employing wet granulation with Croscarmellose Sodium slurry as the granulating fluid 5:
This process ensures uniform Croscarmellose Sodium distribution and optimal particle coating of the API 5. Critical moisture control is essential—residual moisture >5% w/w can cause premature Croscarmellose Sodium activation during storage, while <1% w/w may result in brittle granules with poor compressibility 8.
Direct Compression Approach:
For direct compression ODT formulations (increasingly preferred for manufacturing efficiency) 7:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| PIERRE FABRE MEDICAMENT | Low-dose therapeutic orally disintegrating tablets requiring rapid disintegration (<30 seconds) for patient populations with swallowing difficulties, particularly for antiemetic and gastrointestinal medications. | Orodispersible Domperidone Tablets | Achieved 20-second oral disintegration time using 7% croscarmellose sodium with 50:50 intra-granular/extra-granular distribution, maintaining tablet hardness of 52-54N while outperforming corn starch, crospovidone and croscarmellose calcium alternatives. |
| FMC CORPORATION | Orally disintegrating tablets for resource-limited saliva environments requiring rapid medication delivery, pharmaceutical suspension tablets for pediatric and geriatric populations needing measured-dose suspensions. | Ac-Di-Sol (Croscarmellose Sodium) | Demonstrated superior disintegration efficiency at 2% concentration achieving 18-22 second disintegration times compared to 5% crospovidone requiring 30-40 seconds, with preferred gradual softening pattern and smoother mouthfeel rated by 80% of panelists. |
| DAICEL CORPORATION | Orally disintegrating tablets requiring improved mechanical strength and moisture stability during manufacturing, packaging and handling in humid environments while preserving fast disintegration properties. | ODT Additive Composition | Enhanced tablet moldability by combining 3-8% croscarmellose sodium with 0.5-5% hydrophobic polymers (acrylic/cellulosic derivatives) while maintaining rapid disintegration and moisture resistance in orally disintegrating formulations. |